Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The FDA granted accelerated approval to aducanumab and stated that reduction of amyloid is reasonably likely to predict clinical benefit.
“The FDA has controversially granted accelerated approval to aducanumab and has opined that the reduction of amyloid is reasonably likely to predict clinical benefit 7,9,[98][99][100][101][102][103][104][105][106][107] .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works
Self-citationDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 2× · see citing works
“ing anti-Aß monoclonal antibodies including lecanemab [9], gantenerumab [10], and donanemab [11] and the many”
BackgroundSelf-citationSwanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847 · see citing works
Self-citationStructural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24501-0 · Cited by 364 · see citing works
Alexander, G. C., Emerson, S., & Kesselheim, A. S. (2021) · JAMA · doi:10.1001/jama.2021.3854 · Cited by 240 · see citing works
The “rights” of precision drug development for Alzheimer’s disease
Cummings, J. L., Feldman, H., & Scheltens, P. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0529-5 · Cited by 240 · see citing works
Self-citationKlein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212 · see citing works
IMMEDIATE CARE OF ACUTE BLUNT LARYNGEAL TRAUMA
Nahum, A. M. (1969) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-196902000-00003 · Cited by 57 · see citing works
Sabbagh, M. N., & Cummings, J. L. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12235 · Cited by 45 · see citing works
Self-citationMcCrystal, D., & Bond, C. (2006) · The Journal of Laryngology & Otology · doi:10.1017/s0022215106000909 · Cited by 32 · see citing works
Watson, J., Saunders, S., Terrera, G. M., Ritchie, C. W., Evans, A., Luz, S. F., & Clarke, C. L. (2019) · Health Expectations · doi:10.1111/hex.12876 · Cited by 31 · see citing works
Isolated laryngotracheal separation following blunt trauma to the neck
Offiah, C. J., & Endres, D. (1997) · The Journal of Laryngology & Otology · doi:10.1017/s0022215100139404 · Cited by 21 · see citing works
Management of acute laryngeal trauma.
Eliachar, I. (1996) · PubMed · Cited by 20 · see citing works
Laryngotracheal disruption after blunt neck trauma
Aouad, R. K., Moutran, H., & Rassi, S. J. (2007) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2007.02.048 · Cited by 18 · see citing works
Complete Cricotracheal Separation following Blunt Trauma to the Neck
HERMON, A., Segal, K., Har‐El, G., Abraham, A., & Sidi, J. (1987) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-198712000-00009 · Cited by 16 · see citing works
Vivero, R. J., Saint-Hilaire, R., Bhatia, R. G., & Leibowitz, J. M. (2013) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2013.08.090 · Cited by 9 · see citing works
Complete traumatic laryngo-tracheal separation.
O'Neill, J. P., Shine, N., & Timon, C. A. (2009) · PubMed · Cited by 6 · see citing works
Laryngotracheal reconstruction in total laryngotracheal transection.
Ajmal, M., & Najeeb, T. (2008) · PubMed · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742 · see citing works
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Cummings, J. L., Osse, A. M. L., Cammann, D., Powell, J., & Chen, J. (2023) · BioDrugs · doi:10.1007/s40259-023-00633-2 · Cited by 396 · see citing works
Self-citationJeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306 · see citing works
Dhillon, S. (2021) · Drugs · doi:10.1007/s40265-021-01569-z · Cited by 293 · see citing works
Cummings, J. L. (2023) · Drugs · doi:10.1007/s40265-023-01858-9 · Cited by 249 · see citing works
Self-citationQuantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226 · see citing works
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s325026 · Cited by 183 · see citing works
Withington, C., & Turner, R. S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.862369 · Cited by 151 · see citing works
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US
Ross, E. L., Weinberg, M. S., & Arnold, S. E. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0315 · Cited by 146 · see citing works
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
Walgrave, H., Zhou, L., Strooper, B. D., & Salta, E. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00496-7 · Cited by 132 · see citing works
Rinauro, D. J., Chiti, F., Vendruscolo, M., & Limbocker, R. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00651-2 · Cited by 132 · see citing works
Neuropathogenesis-on-chips for neurodegenerative diseases
Amartumur, S., Nguyen, H. M., Huynh, T., Kim, T. S., Woo, R., Oh, E., Kim, K. K., Lee, L. P., & Heo, C. (2024) · Nature Communications · doi:10.1038/s41467-024-46554-8 · Cited by 120 · see citing works
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Beshir, S. A., Aadithsoorya, A. M., Parveen, A., Goh, S. S. L., Hussain, N., & Menon, V. B. (2022) · International Journal of Alzheimer s Disease · doi:10.1155/2022/9343514 · Cited by 119 · see citing works
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102 · see citing works
Can we learn lessons from the FDA's approval of aducanumab?
Liu, K. Y., & Howard, R. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00557-x · Cited by 104 · see citing works
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?
Kurkinen, M. T., Fułek, M., Fułek, K., Beszłej, J. A., Kurpas, D., & Leszek, J. (2023) · Biomolecules · doi:10.3390/biom13030453 · Cited by 102 · see citing works
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 93 · see citing works
Neuropathology of Anti-Amyloid-β Immunotherapy: A Case Report
Castellani, R. J., Shanes, E. D., McCord, M., Reish, N. J., Flanagan, M. E., Mesulam, M. M., & Jamshidi, P. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221305 · Cited by 84 · see citing works
Complement System in Alzheimer’s Disease
Shah, A., Kishore, U., & Shastri, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413647 · Cited by 76 · see citing works
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.31925 · Cited by 73 · see citing works
Assunção, S. S., Sperling, R. A., Ritchie, C., Kerwin, D. R., Aisen, P. S., Lansdall, C., Atri, A., & Cummings, J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00984-y · Cited by 71 · see citing works
Self-citationBorrajo, M. L., & Alonso, M. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01086-2 · Cited by 70 · see citing works
Patharapankal, E. J., Ajiboye, A. L., Mattern, C., & Trivedi, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010066 · Cited by 69 · see citing works
Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
Nunes, D., Loureiro, J. A., & Pereira, M. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112296 · Cited by 68 · see citing works
Mukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66 · see citing works
Cheng, F., Wang, F., Tang, J., Zhou, Y., Fu, Z., Zhang, P., Haines, J. L., Leverenz, J. B., Gan, L., Hu, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101379 · Cited by 63 · see citing works
Self-citationIndole-Based Compounds in the Development of Anti-Neurodegenerative Agents
Barresi, E., Baglini, E., Poggetti, V., Castagnoli, J., Giorgini, D., Salerno, S., Taliani, S., & Settimo, F. D. (2024) · Molecules · doi:10.3390/molecules29092127 · Cited by 61 · see citing works
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecı̀ć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 51 · see citing works
Morató, X., Pytel, V., Jofresa, S., Ruiz, A., & Boada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169305 · Cited by 53 · see citing works
“Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Makeen, H. A., Albratty, M., Alhazmi, H. A., Felemban, S. G., Alsubayiel, A. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112746 · Cited by 50 · see citing works
Kršek, A., & Batičić, L. (2024) · Future Pharmacology · doi:10.3390/futurepharmacol4020020 · Cited by 49 · see citing works
Digital Technologies to Prevent Social Isolation and Loneliness in Dementia: A Systematic Review
Kaur, H., Kernaghan, D., Schoonmade, L. J., Egan, K. J., & Pot, A. M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220438 · Cited by 46 · see citing works
Small-molecule theranostics in Alzheimer's disease
Sarabia‐Vallejo, Á., López‐Alvarado, P., & Menéndez, J. C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115382 · Cited by 45 · see citing works
Prados, M., Liu, Y., Jun, H., Lam, J., & Mattke, S. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12578 · Cited by 42 · see citing works
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Nimmo, J., Kelly, L., Verma, A. K., Carare, R. O., Nicoll, J. A. R., & Dodart, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733857 · Cited by 40 · see citing works
Wasielewska, J. M., Chaves, J. C. S., Johnston, R. L., Milton, L. A., Hernández, D., Chen, L., Song, J. H., Lee, W., Leinenga, G., Nisbet, R. M., et al. (2022) · Theranostics · doi:10.7150/thno.72685 · Cited by 40 · see citing works
Adenosine receptor signalling in Alzheimer’s disease
Trinh, P. N. H., Baltos, J., Hellyer, S. D., May, L. T., & Gregory, K. J. (2022) · Purinergic Signalling · doi:10.1007/s11302-022-09883-1 · Cited by 42 · see citing works
Bajaj, S., Jain, S., Vyas, P., Bawa, S., & Vohora, D. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.06.022 · Cited by 39 · see citing works
Sanchez-Varo, R. M., Sánchez‐Mejías, E., Fernandez-Valenzuela, J. J., Castro, V. D., Mejias‐Ortega, M., Gómez-Arboledas, Á., Jiménez, S., Sanchez-Mico, M. V., Trujillo‐Estrada, L., Moreno‐González, I., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.752594 · Cited by 38 · see citing works
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 38 · see citing works
Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer’s Disease
Moreira, D. A., Santos, S. D., Leiro, V., & Pêgo, A. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041054 · Cited by 39 · see citing works
“Real world” eligibility for aducanumab
Canevelli, M., Rossi, P. D., Astrone, P., Consorti, E., Vanacore, N., & Cesari, M. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17390 · Cited by 36 · see citing works
Implications of Microorganisms in Alzheimer’s Disease
Yadav, P., Lee, Y., Panday, H., Kant, S., Bajwa, N., Parashar, R., Jha, S. K., Jha, N. K., Nand, P., Lee, S., et al. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100314 · Cited by 37 · see citing works
Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro, S., Valeri, A., & Mazzon, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042011 · Cited by 35 · see citing works
The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimer’s disease
Musardo, S., Therin, S., Pelucchi, S., D’Andrea, L., Stringhi, R., Ribeiro, A., Manca, A., Balducci, C., Pagano, J., Sala, C., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.024 · Cited by 36 · see citing works
Targeting epigenetics: A novel promise for Alzheimer’s disease treatment
Jeremic, D., Jiménez‐Díaz, L., & Navarro‐López, J. D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102003 · Cited by 36 · see citing works
Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Ameen, T. B., Kashif, S. N., Abbas, S. M. I., Babar, K., Ali, S. M. S., & Raheem, A. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00845-5 · Cited by 38 · see citing works
Blood-based biomarkers in Alzheimer’s disease: a mini-review
Padala, S. P., & NEWHOUSE, P. A. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01114-1 · Cited by 35 · see citing works
A History of Senile Plaques: From Alzheimer to Amyloid Imaging
Beach, T. G. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac030 · Cited by 35 · see citing works
Brain simulation augments machine‐learning–based classification of dementia
Triebkorn, P., Stefanovski, L., Dhindsa, K., Díaz-Cortés, M.-A., Bey, P., Bülau, K., Pai, R. K., Spiegler, A., Solodkin, A., Jirsa, V., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12303 · Cited by 31 · see citing works
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Poliwoda, S., Kaye, R. J., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.37023 · Cited by 33 · see citing works
Sighencea, M. G., Popescu, R. Ș., & Trifu, S. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212311 · Cited by 32 · see citing works
Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
Knopman, D. S., & Perlmutter, J. S. (2021) · Neurology · doi:10.1212/wnl.0000000000012452 · Cited by 32 · see citing works
On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer’s Disease
Kriška, J., Heřmanová, Z., Knotek, T., Turečková, J., & Anděrová, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189689 · Cited by 33 · see citing works
“Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
Padovani, A., Caratozzolo, S., Rozzini, L., Pilotto, A., Benussi, A., & Tedeschi, G. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17530 · Cited by 31 · see citing works
The role of basket trials in drug development for neurodegenerative disorders
Cummings, J. L., Montes, A., Kamboj, S., & Cacho, J. R. F. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01015-6 · Cited by 31 · see citing works
Self-citationDave, B. P., Shah, Y. B., Maheshwari, K. G., Mansuri, M. K. A., Prajapati, B., Postwala, H. I., & Chorawala, M. R. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01408-7 · Cited by 32 · see citing works
Jin, M., & Noble, J. M. (2024) · eNeuro · doi:10.1523/eneuro.0088-24.2024 · Cited by 31 · see citing works
Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside
Musiek, E. S., Gómez‐Isla, T., & Holtzman, D. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci154889 · Cited by 30 · see citing works
Nirogi, R., Ieni, J., Goyal, V. K., Ravula, J., Jetta, S., Shinde, A., Jayarajan, P., Benade, V., Palacharla, V. R. C., Dogiparti, D. K., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12307 · Cited by 29 · see citing works
Self-citationRecent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia
Ni, R., & Nitsch, R. M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.751897 · Cited by 29 · see citing works
The amyloid state of proteins: A boon or bane?
Hassan, M. N., Nabi, F., Khan, A. N., Hussain, M. S., Siddiqui, W. A., Uversky, V. N., & Khan, R. H. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.01.115 · Cited by 29 · see citing works
Wang, Y., Wang, K., Yan, J., Zhou, Q., & Wang, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213886 · Cited by 29 · see citing works
An insider's perspective on FDA approval of aducanumab
Wang, Y. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12382 · Cited by 28 · see citing works
Dementia Prevention and Individual and Socioeconomic Barriers: Avoiding “Lifestyle” Stigma
Wilson, N., & Anstey, K. J. (2023) · The Gerontologist · doi:10.1093/geront/gnad130 · Cited by 29 · see citing works
Zhang, P., Hou, Y., Tu, W., Campbell, N. L., Pieper, A. A., Leverenz, J. B., Gao, S., Cummings, J. L., & Cheng, F. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12819 · Cited by 28 · see citing works
Self-citationYeo-Teh, N. S. L., & Tang, B. L. (2023) · Science and Engineering Ethics · doi:10.1007/s11948-022-00422-0 · Cited by 28 · see citing works
Proteostasis unbalance in prion diseases: Mechanisms of neurodegeneration and therapeutic targets
Thellung, S., Corsaro, A., Dellacasagrande, I., Nizzari, M., Zambito, M., & Florio, T. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.966019 · Cited by 26 · see citing works
Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations
Rodriguez‐Porcel, F. E., Wyman‐Chick, K. A., Abdelnour, C., Toledo, J. B., Ferreira, D., Urwyler, P., Weil, R. S., Kane, J. P. M., Pilotto, A., Rongve, A., et al. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00299-w · Cited by 28 · see citing works
Devi, G. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1213968 · Cited by 29 · see citing works
Neurodegenerative Diseases: New Hopes and Perspectives
Bhat, M. A., & Dhaneshwar, S. S. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230907093451 · Cited by 28 · see citing works
Selenium-Derivative Compounds: A Review of New Perspectives in the Treatment of Alzheimer’s Disease
Barbosa, F. A. R., Canto, R. F. S., Teixeira, K. F., de Souza, A. S., de Oliveira, A. S., & Braga, A. L. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220224161454 · Cited by 26 · see citing works
New Insights into Molecular Mechanisms Underlying Neurodegenerative Disorders
Liu, J., Duan, W., Deng, Y., Zhang, Q., Li, R., Long, J., Waqas, A., Gu, C., Qiu, Y., Cai, H., et al. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2203058 · Cited by 26 · see citing works
Syed, A. U., Liang, C., Patel, K. K., Mondal, R., Kamalia, V. M., Moran, T. R., Ahmed, S. T., & Mukherjee, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310808 · Cited by 26 · see citing works
Aducanumab in Alzheimer’s Disease: A Critical Update
Ashique, S., Sirohi, E., Kumar, S., Rihan, M., Mishra, N., Bhatt, S., Gautam, R. K., Singh, S. K., Gupta, G., Chellappan, D. K., et al. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230727103553 · Cited by 26 · see citing works
Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update
Khan, S. S., Khatik, G. L., & Datusalia, A. K. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411083922 · Cited by 25 · see citing works
Sandberg, A., Berenjeno‐Correa, E., Rodriguez, R. C., Axenhus, M., Weiss, S. S., Batenburg, K. L., Hoozemans, J. J. M., Tjernberg, L. O., & Scheper, W. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01141-1 · Cited by 25 · see citing works
Padala, S. P., & Yarns, B. C. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220023 · Cited by 24 · see citing works
Petrisko, T. J., Gómez-Arboledas, Á., & Tenner, A. J. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.09.003 · Cited by 22 · see citing works
Sun, F., Zhao, J. J., Zhang, H., Shi, Q., Liu, Y., Robert, A., Liu, Q., & Meunier, B. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00455 · Cited by 24 · see citing works
Quantitative proteomics of tau and Aβ in detergent fractions from Alzheimer's disease brains
Mukherjee, S., Dubois, C., Perez, K. A., Varghese, S., Birchall, I. E., Leckey, M., Davydova, N., McLean, C., Nisbet, R. M., Roberts, B. R., et al. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15713 · Cited by 21 · see citing works
Séguy, L., Groo, A., & Malzert‐Fréon, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.022 · Cited by 22 · see citing works
Marín, A., DeCaro, R. E., Schiloski, K. A., El‐Shaar, A., Dwyer, B. C., Vives‐Rodriguez, A., Palumbo, R., Turk, K. W., & Budson, A. E. (2022) · JMIR Formative Research · doi:10.2196/34450 · Cited by 22 · see citing works
MicroRNAs in Learning and Memory and Their Impact on Alzheimer’s Disease
Wang, I., Ho, P., & Tsai, K. (2022) · Biomedicines · doi:10.3390/biomedicines10081856 · Cited by 21 · see citing works
An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure
Boopathi, S., Poma, A. B., & Garduño‐Juárez, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910798 · Cited by 20 · see citing works
Wang, G., Liu, L., Li, Y., Aschenbrenner, A. J., Bateman, R. J., Delmar, P., Schneider, L. S. S., Kennedy, R., Cutter, G., & Xiong, C. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12286 · Cited by 20 · see citing works
Punyakoti, P., Behl, T., Sehgal, A., Yadav, S., Sachdeva, M., Anwer, M. K., Vargas-De-La-Cruz, C. B., Venkatachalam, T., Naqvi, M., Verma, R., et al. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110539 · Cited by 20 · see citing works
Huang, L., Zeng, Y., Li, Y., Zhu, Y., He, Y., Liu, Y., Robert, A., & Meunier, B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122691 · Cited by 18 · see citing works
Webberley, T. S., Bevan, R. J., Kerry-Smith, J., Dally, J., Michael, D. R., Thomas, S., Rees, M. E., Morgan, J. E., Marchesi, J. R., Good, M. A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054683 · Cited by 19 · see citing works
Mo, H., Kim, J., Kim, J. Y., Kim, J. W., Han, H., Choi, S. H., Rim, Y. A., & Ju, J. H. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00384-8 · Cited by 21 · see citing works
Hoffmann, T., Rahfeld, J., Schenk, M., Ponath, F., Makioka, K., Hutter‐Paier, B., Lues, I., Lemere, C. A., & Schilling, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111791 · Cited by 23 · see citing works
Self-citationNow is the Time to Improve Cognitive Screening and Assessment for Clinical and Research Advancement
Ashford, J. W., Schmitt, F. A., Bergeron, M. F., Bayley, P. J., Clifford, J. O., Xu, Q., Liu, X., Zhou, X., Kumar, V., Herman Buschke, L., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220211 · Cited by 18 · see citing works
Utomo, R. Y., Sugie, A., Okada, S., Miura, K., & Nakamura, H. (2022) · Chemical Communications · doi:10.1039/d1cc07000b · Cited by 18 · see citing works
Marsool, M. D. M., Prajjwal, P., Reddy, Y. B., Marsool, A. D. M., Lam, J. R., & Nandwana, V. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101547 · Cited by 18 · see citing works
Francisco, T. N., Malafaia, D., Melo, L., Silva, A. M. S., & Albuquerque, H. M. T. (2024) · ACS Omega · doi:10.1021/acsomega.3c10417 · Cited by 18 · see citing works
Donanemab: Not two without a third
Kurkinen, M. T. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/172673 · Cited by 17 · see citing works
The Effects and Mechanisms of Xanthones in Alzheimer’s Disease: A Systematic Review
Pang, L. W., Hamzah, S. B., Tan, S. L. J., Mah, S. H., & Yow, H.-Y. (2023) · Neurochemical Research · doi:10.1007/s11064-023-04005-8 · Cited by 16 · see citing works
Marcolini, S., Frentz, I., Sánchez-Catasús, C. A., Mondragón, J. D., Feltes, P. K., van der Hoorn, A., Borra, R., Ikram, M. A., Dierckx, R., & Deyn, P. P. D. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101661 · Cited by 15 · see citing works
Amyloid –β pathology in Alzheimer’s disease: A nano delivery approach
Meghana, G. S., Gowda, D., Chidambaram, S. B., & Osmani, R. A. M. (2023) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2023.103510 · Cited by 16 · see citing works
Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer’s disease
Boada, M., Martínez‐Lage, P., Serrano-Castro, P. J., Costa, M., & Páez, A. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1960823 · Cited by 15 · see citing works
- Authors
- Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S.
- Affiliations
- University of Nevada, Las Vegas (US)
- University of Southern California (US)
- Brigham and Women's Hospital (US)
- Cleveland Clinic (US)
- Brown University (US)
- Corresponding author
- Cummings, Jeffrey
- Venue
- Alzheimer's Research & Therapy
- Published
- 2021-05-10
- Volume
- 13
- Issue
- 1
- Pages
- 98-98
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC8111757
- OpenAlex
- W3161140821
- Cited by
- 224
- References
- 19
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 31 · 2023: 52 · 2022: 87 · 2021: 31 · 2013: 1
- FWCI
- 31.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of General Medical Sciences (P20GM109025)
- National Institute of Neurological Disorders and Stroke (U01NS093334)
- National Institute on Aging (R01AG053798, P20AG068053, R35AG71476)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- aducanumab, amyloid-beta, Alzheimer's disease, anti-amyloid therapy, clinical benefit
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Amyloid beta-Peptides, Amyloidogenic Proteins, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
